Long-Term Effectiveness of Dupilumab in Patients with Atopic Dermatitis: Results up to 3 Years from the RELIEVE-AD Study-Reference-Cited by-同舟云学术

Long-Term Effectiveness of Dupilumab in Patients with Atopic Dermatitis: Results up to 3 Years from the RELIEVE-AD Study

Published:2023-08-08 Issue:9 Volume:13 Page:2107-2120
ISSN:2193-8210
Container-title:Dermatology and Therapy
language:en
Short-container-title:Dermatol Ther (Heidelb)

Author:

Kimball Alexa B.,Delevry Dimittri,Yang Min,Chuang Chien-Chia,Wang Zhixiao,Bégo-Le-Bagousse Gaëlle,Martins Bruno,Wu Eric,Shumel Brad,Wang Jessie,Sierka Debra,Chao Jingdong,Strober Bruce

Funder

Regeneron Pharmaceuticals

Sanofi

Publisher

Springer Science and Business Media LLC

Subject

Dermatology

Link

https://link.springer.com/content/pdf/10.1007/s13555-023-00965-5.pdf

Reference31 articles.

1. Eckert L, Gupta S, Amand C, Gadkari A, Mahajan P, Gelfand JM. Impact of atopic dermatitis on health-related quality of life and productivity in adults in the United States: an analysis using the national health and wellness survey. J Am Acad Dermatol. 2017;77(2):274-9.e3.

2. de Bruin-Weller M, Gadkari A, Auziere S, et al. The patient-reported disease burden in adults with atopic dermatitis: a cross-sectional study in Europe and Canada. J Eur Acad Dermatol Venereol. 2020;34(5):1026–36.

3. Luger T, Romero WA, Gruben D, Smith TW, Cha A, Neary MP. Clinical and humanistic burden of atopic dermatitis in Europe: analyses of the national health and wellness survey. Dermatol Ther (Heidelb). 2022;12(4):949–69.

4. Anderson P, Austin J, Lofland JH, Piercy J, Joish VN. Inadequate disease control, treatment dissatisfaction, and quality-of-life impairments among US patients receiving topical therapy for atopic dermatitis. Dermatol Ther (Heidelb). 2021;11(5):1571–85.

5. Wei W, Ghorayeb E, Andria M, et al. A real-world study evaluating adeQUacy of Existing Systemic Treatments for patients with moderate-to-severe Atopic Dermatitis (QUEST-AD): baseline treatment patterns and unmet needs assessment. Ann Allergy Asthma Immunol. 2019;123(4):381–8.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Does Body Mass Index Impact the Clinical Response to Dupilumab Therapy in Atopic Dermatitis? A Monocentric Study of 170 Patients;Journal of Clinical Medicine;2024-08-05

2. Prolonged hypereosinophilia associated with dupilumab for atopic dermatitis: A case series and review of literature;JAAD Case Reports;2024-08

3. Practical Management of the JAK1 Inhibitor Abrocitinib for Atopic Dermatitis in Clinical Practice: Special Safety Considerations;Dermatology and Therapy;2024-07-02

4. Assessment of Patient-Reported Outcomes at 48 Months of Treatment with Dupilumab for Severe Atopic Dermatitis: A Single-Center Real-Life Experience with 126 Patients;Pharmaceuticals;2024-01-16

5. Long-Term Efficacy and Safety of Dupilumab in Patients with Atopic Dermatitis: A Single-Centre Retrospective Study;Cosmetics;2023-11-07